Royal Marsden Hospital
Head of radioisotope physics
Dr Glenn Flux is Head of Radioisotope Physics at the Royal Marsden Hospital and Institute of Cancer Research in Sutton, UK. His main research focus is on translational quantitative SPECT and PET imaging and its application to internal dosimetry for molecular radiotherapy. He has been involved in the development of imaging and dosimetry for clinical procedures including I-131 mIBG treatment of neuroblastoma and the treatment and palliation of bone metastases from prostate cancer with Re-186 HEDP and Ra-223. He has published over 100 peer reviewed articles and received research funding from national and international bodies. He is a founder member of the EANM Dosimetry Committee and is currently chair of the British Nuclear Medicine Society Molecular Radiotherapy committee.
The emergence and resurgence of radiotherapeutics for cancer treatment
Cancer treatment with radiopharmaceuticals is growing rapidly with many new radiotherapeutics either in development or early phase trials. Molecular radiotherapy and theragnostics promise to offer significant advances in cancer care and the market is expected to grow by 30% per annum for the foreseeable future. This presentation will review the potential impact of this expansion for industry, academia, and patient benefit.
EVEN MORE SEMINARS
Sanjay Prabhu, MBBS Harvard Medical School / Boston Children’s Hospital
3D printing, virtual surgery and mixed reality in the OR - fad or trend?
Dr Simon P.G. Padley Royal Brompton Hospital
An approach to diffuse lung disease: Learn from the experts
Dr Arjun Nair The Harley Street Clinic (Part of HCA healthcare UK)
Advance Technologies in Diagnostics
Mike Tanner EPSRC Proteus / Heriot-Watt University & University of Edinburgh
Locating medical devices through early arriving single photon imaging
Sofia Otero University College London Hospitals
Thyroid Radiofrequency Ablation: Our Experience